CVS Health said it will prefer lower-cost interchangeable biosimilars over Johnson & Johnson’s Stelara on its most common drug lists starting July 1. The move is a modest headwind for Stelara’s market access and reflects continued payer pressure to shift utilization toward lower-cost biologics. The direct market impact is likely limited, but the change is directionally negative for J&J’s psoriasis franchise.
CVS Health said it will prefer lower-cost interchangeable biosimilars over Johnson & Johnson’s Stelara on its most common drug lists starting July 1. The move is a modest headwind for Stelara’s market access and reflects continued payer pressure to shift utilization toward lower-cost biologics. The direct market impact is likely limited, but the change is directionally negative for J&J’s psoriasis franchise.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly negative
Sentiment Score
-0.20
Ticker Sentiment
